Pregnancy control in Patients with Systemic Lupus Erythematosus/Antiphospholipid Syndrome. Part 3: Childbirth. Puerperium. Breastfeeding Contraception. Newborn
Por:
Delgado P, Robles Á, Martínez López JA, Sáez-Comet L, Rodríguez Almaraz E, Martínez-Sánchez N, Ugarte A, Vela C, Marco B, Espinosa G, Galindo M, Casellas M, Ruiz-Irastorza G, Martínez-Taboada V and Bartha JL
Publicada:
1 abr 2021
Ahead of Print:
1 mar 2021
Categoría:
Rheumatology
Resumen:
Objective: In order to agree on the fundamental aspects related to the management of pregnancy in patients with systemic lupus erythematosus and antiphospholipid syndrome, the Spanish Societies of Gynaecology and Obstetrics, Internal Medicine and Rheumatology have set up a working group for the preparation of three consensus documents.
Methods: Each of the Scientific Societies involved proposed five representatives based on their experience in the field of pregnancy control in patients with autoimmune diseases. The recommendations were developed following the Delphi methodology.
Results: This third document contains the recommendations regarding the management of delivery, puerperium and lactation, including medication use during these periods and the care of the newborn. In addition, a section on contraception is included.
Conclusions: These multidisciplinary recommendations are considered decision-making tools for clinicians involved in the care of patients with systemic lupus erythematosus/antiphospholipid syndrome during pregnancy. (c) 2019 Elsevier Espana, S.L.U. and Sociedad Espanola de Reumatologia y Colegio Mexicano de Reumatologia. All rights reserved.
Filiaciones:
Delgado P:
Servicio de Obstetricia y Ginecología, Biocruces Bizkaia Health Research Institute, Hospital Universitario Cruces, Barakaldo, Bizkaia, España
Robles Á:
Servicio de Medicina Interna, Hospital Universitario La Paz, Madrid, España
Martínez López JA:
Servicio de Reumatología, Hospital Universitario Fundación Jiménez Díaz, Madrid, España
Sáez-Comet L:
Unidad de Enfermedades Autoinmunes Sistémicas (UEAS), Servicio de Medicina Interna, Hospital Universitario Miguel Servet, Zaragoza, España
Rodríguez Almaraz E:
Servicio de Reumatología, Hospital 12 de Octubre, Madrid, España
Martínez-Sánchez N:
Servicio de Obstetricia y Ginecología, Hospital Universitario La Paz, Madrid, España
Ugarte A:
Unidad de Enfermedades Autoinmunes, Servicio de Medicina Interna, BioCruces Bizkaia Health Research Institute, Hospital Universitario Cruces, UPV/EHU, Barakaldo, Bizkaia, España
Vela C:
Sección de Reumatología, Hospital Universitario de Alicante, Instituto de investigaci ón sanitaria y biomédica ISABIAL - FISABIO, Departamento de Medicina Clínica, Universidad Miguel Hernandez, Alicante, España
Marco B:
Servicio de Ginecología y Obstetricia, HUP La Fe, Valencia, España
Espinosa G:
Department of Autoimmune Diseases, Hospital Clinic, Biological aggresion and response mechanisms, IDIBAPS, Barcelona, Universitat de Barcelona, España
Galindo M:
Servicio de Reumatología, Hospital 12 de Octubre, Madrid, España
Casellas M:
Unitat Alt Risc Obstetric, Vall d' Hebron Hospital Campus, Barcelona, España
Ruiz-Irastorza G:
Unidad de Enfermedades Autoinmunes, Servicio de Medicina Interna, BioCruces Bizkaia Health Research Institute, Hospital Universitario Cruces, UPV/EHU, Barakaldo, Bizkaia, España
Martínez-Taboada V:
Servicio de Reumatología, Hospital Universitario Marqués de Valdecilla, IDIVAL, Facultad de Medicina, Universidad de Cantabria, Santander, España
Bartha JL:
Servicio de Obstetricia y Ginecología, Hospital Universitario La Paz, Madrid, España
Green Accepted
FULL TEXT
 |
Published Version |
This policy does not allow for Open Access for this version. |
| No Accesible |
|